FMC63 scFv, His Tag

제품 번호/규격
가격
Availability
수량
CD9-M52Hb-100ug
$225.00
In Stock - Delivery in 1-2 business days
CD9-M52Hb-1mg (500ug X 2)
$1,635.00
In Stock - Delivery in 1-2 business days
CD9-M52Hb
제품 금액 :
$ 0
신제품 제안 Request Quote
Contact Us
Contact Us
제품 금액:
$ 0
  • 제품 세부정보
  • 데이터 표시
  • Reviews & Citations
  • Important Statement
  • Resources
Source

FMC63 scFv, His Tag is a recombinant single-chain variable fragment derived from the mouse monoclonal antibody clone FMC63 and expressed in HEK293 cells.

Antibody Type

Recombinant Monoclonal

Clone

FMC63

Host Species

Mouse

Reactivity

Human

Immunogen

CD19

Specificity

Specifically recognizes the CD19.

Application
Application
Recommended Use
ELISA
0.2-2 μg/mL

* Recommended dilutions are for reference only. Optimal working concentrations may vary depending on your consumables, reagents, and assay conditions. We recommend optimizing for your specific system. No warranty is made regarding performance at any specific dilution.

Purification

Affinity purification.

Aggregation

Less than 5%, as determined by SEC-MALS.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

배경 소개

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.